Element Wealth LLC Reduces Holdings in Invesco Pharmaceuticals ETF (NYSEARCA:PJP)

Element Wealth LLC lowered its position in Invesco Pharmaceuticals ETF (NYSEARCA:PJP) by 15.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,570 shares of the company’s stock after selling 839 shares during the quarter. Element Wealth LLC’s holdings in Invesco Pharmaceuticals ETF were worth $378,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Howe & Rusling Inc. purchased a new stake in Invesco Pharmaceuticals ETF in the 3rd quarter worth about $48,000. FMR LLC grew its stake in shares of Invesco Pharmaceuticals ETF by 29.4% during the third quarter. FMR LLC now owns 1,057 shares of the company’s stock valued at $92,000 after buying an additional 240 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Invesco Pharmaceuticals ETF by 241.7% during the third quarter. JPMorgan Chase & Co. now owns 4,046 shares of the company’s stock valued at $352,000 after buying an additional 2,862 shares during the last quarter. Grimes & Company Inc. purchased a new stake in shares of Invesco Pharmaceuticals ETF in the fourth quarter worth approximately $354,000. Finally, Arete Wealth Advisors LLC bought a new stake in shares of Invesco Pharmaceuticals ETF during the 3rd quarter worth approximately $402,000.

Invesco Pharmaceuticals ETF Stock Down 0.4 %

Shares of Invesco Pharmaceuticals ETF stock opened at $86.54 on Friday. The stock’s fifty day moving average is $84.35 and its two-hundred day moving average is $85.87. Invesco Pharmaceuticals ETF has a 52 week low of $75.33 and a 52 week high of $89.87. The company has a market capitalization of $263.95 million, a PE ratio of 24.54 and a beta of 0.58.

Invesco Pharmaceuticals ETF Profile

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.